Moderna Inc., the Cambridge, Massachusetts-based American biotech company which has shown promising results at its Phase 2 human clinical trial for the pandemic vaccine, said in a statement on Sunday that the American biotech company had received further $472 million in aid from the US Government’s Biomedical Advanced Research and Development Authority (BARDA) to help finance its third-stage human clinical trial which would likely to involve over 30,000 volunteers.
Aside from that, the US-based vaccine maker had also added at its statement that the financing would back its late-stage clinical development of the pandemic vaccine. In point of fact, back in April this year, Moderna Inc.
had received $483 million from a US Federal Agency that usually finances the therapeutic technology, however, Moderna Inc.’s pandemic vaccine had been in an early-stage clinical trial, while the latest financial support for the experimental vaccine of Moderna, the first biotech company in the US to start off a human trial for its pandemic vaccine, had totalled the funding at about $955 million.
Moderna Inc. CEO claims pandemic vaccine could prevent future outbreak
Meanwhile, shortly after the announcement of the BARDA financing on Sunday, voicing an out and out optimism over the vaccine maker’s success at human clinical trials, Moderna Inc.
Chief Executive Stephane Bancel said in a press release, “Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks. ” Besides, the company had told earlier that at its Phase three clinical study, scheduled to begin by July 27 in collaboration with the National Institute of Allergy and Infectious Diseases, would involve about 30,000 participants.
Moderna Inc.’s pandemic vaccine capitalizes on an mRNA-based technology that could help a human body become immunized against the pandemic more potentially and could be developed and manufactured at a higher rate than the traditional vaccines, suggested experts.